We review the current status of gene therapy for inherited retinal disorders, discussing preoperative evaluation, surgery, and follow up with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute.

We discuss the use of a suprachoroidal delivery system for delivery of tryrosinase kinase inhibitor for the treatment of neovascular AMD with Dr. Thomas Ciulla, Chief Development Officer, Chief Medical Officer, Clearside Biomedical.

We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.

We discuss the  use of intravitreal avacincaptad peg for the treatment of geographic atrophy in two randomized trials, Gather 1 and Gather 2 with Dr. Arshad Khanani, Sierra Eye Associates, Reno Nevada and Associate Clinical Professor University of Nevada Reno.

We discuss the role that en-face optical coherence tomography (OCT) can play in understanding the evolution of intermediate AMD and geographic atrophy with Dr. Philip Rosenfeld, Professor of Ophthalmology, Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine.

We review the 24 month results of the Derby and Oaks trials, with emphasis on the safety of pegcetcoplan with Caroline Baumal, MD, Professor of Ophthalmology Tufts University School of Medicine and the New England Eye Center.

Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia at Augusta University discusses the value of ultra wide field imaging in assessing diabetic retinopathy worsening over time.

Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.

Dr. Susanna Park reviews current therapy of retinal branch and central vein occlusion and discusses a Phase I trial (the TRUST study) investigating the use of intravitreal autologous stem cells as a possible treatment for central vein occlusion. 

Dr. Susanna Park, Professor of Ophthalmology, Roth Endowed Chair in Visual Science at the University of California, Davis

We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.